T12311 |
Tirabrutinib hydrochloride
|
1439901-97-9
|
98.90%
|
|
Tirabrutinib hydrochloride (GS-4059 (hydrochloride)) is a selective and novelBTK with IC50 2.2 nm inhibitor.
|
T38960L |
QL-X-138 HCl
|
|
98.89%
|
|
QL-X-138 HCl is a novel selective and highly potent BTK/MNK dual-kinase inhibitor with anticancer activity that binds covalently to BTK and noncovalently to MNK....
|
T9072 |
Tuxobertinib
|
2414572-47-5
|
98.86%
|
|
Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK a...
|
TQ0242 |
Fenebrutinib
|
1434048-34-6
|
98.84%
|
|
Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
|
T10626 |
(Rac)-IBT6A
|
1412418-47-3
|
98.68%
|
|
(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
|
T10870L |
CP-547632
|
252003-65-9
|
98.51%
|
|
CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is ...
|
T73334 |
Larotinib
|
1438072-11-7
|
98.45%
|
|
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
|
T38960 |
QL-X-138
|
1469988-63-3
|
98.41%
|
|
QL-X-138 is a potent and selective BTK and MNK dual kinase inhibitor that binds covalently to BTK and non-covalently to MNK.The IC 50 s of QL-X-138 against BTK, ...
|
T2472 |
CGI-1746
|
910232-84-7
|
98.27%
|
|
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
|
TQ0039 |
(±)-Zanubrutinib
|
1633350-06-7
|
98.19%
|
|
(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achiev...
|
T73463 |
NX-2127
|
2416131-46-7
|
98.11%
|
|
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activ...
|
T64124 |
Sunvozertinib
|
2370013-12-8
|
98.11%
|
|
Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inh...
|
T9192 |
BIIB068
|
1798787-27-5
|
98.05%
|
|
BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
|
T13447 |
(R)-Zanubrutinib
|
1691249-44-1
|
98.04%
|
|
(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
|
T4387 |
Evobrutinib
|
1415823-73-2
|
98.04%
|
|
Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the deve...
|
T6078 |
Saracatinib
|
379231-04-6
|
98.03%
|
|
Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
|
T12542 |
Rilzabrutinib
|
1575596-29-0
|
97.87%
|
|
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
|
T2603 |
Spebrutinib
|
1202757-89-8
|
97.14%
|
|
Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity...
|
T13564 |
AZ7550
|
1421373-99-0
|
97.07%
|
|
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
|
T16157 |
MT-802
|
2231744-29-7
|
97%
|
|
MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
|